Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer

Next Previous
Trial Profile

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Prexasertib (Primary)
  • Indications Advanced breast cancer; Carcinoma; Fallopian tube cancer; Male breast cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Triple negative breast cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 06 Jun 2023 Results of exploratory analysis assessing the role of innate immune system in modulating CHK1 inhibitor (CHK1i) response in ovarian cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 19 Apr 2023 Results of preliminary analysis(n=49 of biopsy cohort: n=25 and non-biopsy cohort: n=24) assessing biomarker analysis of prexasertib in BRCA wild-type platinum-resistant recurrent, high-grade serous ovarian cancer presented at the 114th Annual Meeting of the American Association for Cancer Research
    • 11 Aug 2022 Status changed from completed to discontinued (Eli Lilly prematurely terminated the study)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top